SUMMARY: The American Cancer Society estimates that for 2025, about 23,690 new cases of Chronic Lymphocytic Leukemia (CLL) will be diagnosed in the US and 4460 patients will die of the disease. CLL accounts for about one-quarter of the new cases of leukemia. The average age of patients diagnosed with CLL is around 70 years, and is rarely seen in people under age 40, and is extremely rare in children. Patients with CLL often receive continuous therapy with either Brutons Tyrosine Kinase (BTK) inhibitors, time limited therapy with BCL2 inhibitor Venetoclax (VENCLEXTA®) given along with anti-CD20 antibody Obinutuzumab, or under certain circumstances, chemoimmunotherapy.
BTK inhibitors approved in the US include first-generation irreversible inhibitor Ibrutinib (IMBRUVICA®), second-generation covalent inhibitors Acalabrutinib (CALQUENCE®) and Zanubrutinib (BRUKINSA®), and the third-generation, reversible (non-covalent) inhibitor Pirtobrutinib (JAYPIRCA®).
Continuous BTK inhibition improves outcomes but is associated with resistance and toxicity over time. Given the complementary mechanisms of action, the combination of Ibrutinib and Venetoclax has been evaluated in multiple trials. Notably, fixed-duration combination therapy improved Progression-Free Survival (PFS) and Overall Survival (OS) compared with chemoimmunotherapy in the GLOW and CAPTIVATE studies, while the CLARITY trial demonstrated the feasibility of Measurable Residual Disease (MRD)-guided therapy in relapsed/refractory CLL.
The Phase 3 FLAIR trial expands this investigation in previously untreated CLL patients, testing whether MRD-guided Ibrutinib–Venetoclax can improve long-term outcomes compared with Ibrutinib alone or Fludarabine, Cyclophosphamide and Rituximab combination (FCR).
Trial Design
- Population: Patients with previously untreated CLL.
- Randomization (1:1:1):
- Ibrutinib–Venetoclax (N=260)
- Ibrutinib monotherapy (N=263)
- FCR (N=263)
- Treatment Regimens:
- FCR: Six 28-day cycles of Fludarabine, Cyclophosphamide, and Rituximab.
- Ibrutinib monotherapy: 420 mg orally daily, up to 6 years.
- Ibrutinib–Venetoclax: Eight-week Ibrutinib lead-in followed by Venetoclax ramp-up to 400 mg daily. Treatment duration (2–6 years) was MRD-guided, with discontinuation allowed after sustained MRD negativity.
- Primary endpoints:
- Undetectable MRD in bone marrow within 2 years (Ibrutinib–Venetoclax vs single agent Ibrutinib).
- PFS (Ibrutinib–Venetoclax vs FCR).
- Secondary endpoints: PFS (Ibrutinib–Venetoclax vs Ibrutinib alone), OS, and safety.
Key Results
With a median follow-up of 62.2 months, the findings strongly favored the Ibrutinib–Venetoclax combination arm:
- MRD Negativity (Bone Marrow, ≤2 years):
- 66.2% with Ibrutinib–Venetoclax combination vs 0% with Ibrutinib alone (P<0.001)
- 48.3% with FCR
- Progression-Free Survival (5 years):
- 93.9% (Ibrutinib–Venetoclax) vs 79.0% with Ibrutinib alone and 58.1% with FCR
- HR for progression or death = 0.29 (Ibrutinib–Venetoclax vs single agent Ibrutinib, P<0.001), and 0.13 (Ibrutinib–Venetoclax vs FCR, P<0.001)
- 93.9% (Ibrutinib–Venetoclax) vs 79.0% with Ibrutinib alone and 58.1% with FCR
- Estimated Overall Survival (5 years):
- 95.9% (Ibrutinib–Venetoclax) vs 90.5% with Ibrutinib alone and 86.5% with FCR
- HR for death: 0.41 (Ibrutinib–Venetoclax vs Ibrutinib), and 0.26 (Ibrutinib–Venetoclax vs FCR)
- 95.9% (Ibrutinib–Venetoclax) vs 90.5% with Ibrutinib alone and 86.5% with FCR
- IGHV Subgroup Analysis:
- Unmutated IGHV: Strongest OS benefit with Ibrutinib–Venetoclax compared to Ibrutinib alone (HR for death = 0.30), and compared to FCR (HR for death = 0.16). The Ibrutinib alone group and the FCR group had similar results for OS.
- Mutated IGHV: Overall Survival outcomes were similar between Ibrutinib–Venetoclax and Ibrutinib alone.
- Treatment Exposure:
Median duration of Ibrutinib–Venetoclax was 35 months. The percentage of patients with undetectable MRD in peripheral blood at 2 years was 73.1% in the Ibrutinib–Venetoclax group, 0% in the Ibrutinib-alone group, and 60.8% in the FCR group. The median time to the first occurrence of undetectable MRD in peripheral blood was 13.0 months in the Ibrutinib–Venetoclax group, and was 8.9 months in the FCR group. - Safety:
No new safety signals were reported. Atrial fibrillation and hypertension were more frequent in Ibrutinib-containing arms than FCR, but were manageable with cardiovascular risk optimization. Rates of sudden death were low and similar across groups.
Clinical Implications
The FLAIR trial reinforces MRD-guided Ibrutinib–Venetoclax as a highly effective strategy for previously untreated CLL, achieving durable disease control and survival benefits beyond both continuous BTK inhibitor monotherapy and FCR.
Key takeaways for practice:
- Deep remissions: Two-thirds of patients achieved bone marrow MRD negativity with Ibrutinib–Venetoclax combination, within 2 years, a strong surrogate for long-term disease control.
- Superior survival: The 5-year PFS and OS rates with Ibrutinib–Venetoclax combination therapy exceed historical outcomes with continuous BTK inhibition or fixed-duration Venetoclax regimens.
- IGHV status matters: Patients with unmutated IGHV appear to derive the greatest benefit, whereas outcomes are more similar across strategies in mutated IGHV.
- Individualized therapy feasible: MRD-guided discontinuation allowed many patients to stop treatment early, balancing efficacy with reduced exposure.
While questions remain regarding optimal duration, cost-effectiveness, and the logistics of real-time MRD monitoring, FLAIR provides compelling evidence that tailored combination therapy could redefine first-line management of CLL, particularly for patients with unmutated IGHV.
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia. Munir T, Girvan S, Cairns DA, et al. for the UK CLL Trials Group. N Engl J Med 2025;393:1177-1190
